SCHEMBL4430192

SCHEMBL4430192

COc1cc(C)ccc1S(=O)(=O)N1CC2C([CH]c3ccc(N4CCOCC4)c(F)c3)C2C1

nearest known ligand 0.44

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MCOLN3 Q8TDD5 1/20 0.44
ALDH1A1 P00352 6/20 0.42
POLB P06746 1/20 0.42
KDM1A O60341 1/20 0.42
MAPT P10636 3/20 0.41
LMNA P02545 2/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
TSHR P16473 2/20 0.40
TP53 P04637 1/20 0.40
HSD17B10 Q99714 1/20 0.40
HPGD P15428 1/20 0.40
NPSR1 Q6W5P4 1/20 0.39
KMT2A Q03164 4/20 0.39
MEN1 O00255 2/20 0.39
USP2 O75604 1/20 0.38
GAA P10253 1/20 0.38
PKM P14618 1/20 0.37
HTT P42858 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4552447 0.81 MCOLN3 (0.42) MCOLN3ALDH1A1POLBMAPTLMNA
SCHEMBL4552446 0.80 EPHX2 (0.47) MCOLN3ALDH1A1POLBMAPTLMNA
SCHEMBL4420883 0.78 LMNA (0.45) ALDH1A1MAPTLMNASMN1; SMN2HPGD
SCHEMBL4421354 0.76 SLC6A9 (0.43) ALDH1A1MAPTLMNASMN1; SMN2HSD17B10
SCHEMBL4424440 0.76 HSD11B1 (0.41) KDM1AMAPTLMNASMN1; SMN2KMT2A
SCHEMBL4431014 0.74 LMNA (0.43) ALDH1A1POLBKDM1ALMNASMN1; SMN2
SCHEMBL4424423 0.73 ALDH1A1 (0.40) ALDH1A1KDM1AMAPTLMNASMN1; SMN2
SCHEMBL18887217 0.72 KMT2A (0.37) MCOLN3ALDH1A1POLBMAPTLMNA
SCHEMBL4421900 0.72 LMNA (0.40) ALDH1A1POLBKDM1ALMNASMN1; SMN2
SCHEMBL4418783 0.71 KMT2A (0.42) ALDH1A1POLBKDM1AMAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7473787-B2 Bicyclic [3.1.0] derivatives as glycine transporter inhibitors PFIZER INC (US) 2009-01-06 US disclosed
US-20050096375-A1 Bicyclic [3.1.0] derivatives as glycine transporter inhibitors PFIZER INC. 2005-05-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050096375-A1 Bicyclic [3.1.0] derivatives as glycine transporter inhibitors SLC6A5, SLC1A5, SLC6A3 MCOLN3 2228/4885ALDH1A1 3166/4885POLB 2927/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.